Pfizer Inc. (NYSE:PFE) Shares Purchased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 52.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 6,373,492 shares of the biopharmaceutical company's stock after acquiring an additional 2,191,326 shares during the quarter. Pfizer accounts for approximately 0.5% of Assenagon Asset Management S.A.'s holdings, making the stock its 26th largest holding. Assenagon Asset Management S.A. owned 0.11% of Pfizer worth $183,493,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. RB Capital Management LLC lifted its holdings in Pfizer by 6.7% in the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company's stock valued at $282,000 after acquiring an additional 341 shares during the period. Ironwood Wealth Management LLC. raised its stake in shares of Pfizer by 1.1% during the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company's stock worth $1,868,000 after buying an additional 400 shares during the period. United Bank raised its stake in shares of Pfizer by 0.6% during the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company's stock worth $2,416,000 after buying an additional 290 shares during the period. Ergoteles LLC raised its stake in shares of Pfizer by 136.3% during the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company's stock worth $1,903,000 after buying an additional 21,209 shares during the period. Finally, Mackenzie Financial Corp raised its stake in shares of Pfizer by 6.4% during the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company's stock worth $69,238,000 after buying an additional 79,887 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Analysts Set New Price Targets

Several research firms recently commented on PFE. Cantor Fitzgerald reissued an "overweight" rating and issued a $45.00 price objective on shares of Pfizer in a research note on Friday, March 1st. TD Cowen downgraded Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 price objective for the company. in a research note on Thursday, January 4th. Truist Financial reduced their price objective on Pfizer from $42.00 to $36.00 and set a "buy" rating for the company in a research note on Thursday, December 14th. Argus downgraded Pfizer from a "buy" rating to a "hold" rating in a research note on Friday. Finally, Barclays dropped their target price on Pfizer from $34.00 to $28.00 and set an "equal weight" rating for the company in a report on Thursday, December 14th. Twelve analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $36.88.

Pfizer Stock Performance

Shares of PFE stock traded up $0.07 during midday trading on Monday, hitting $27.43. The company had a trading volume of 31,099,552 shares, compared to its average volume of 44,150,801. The company's 50 day simple moving average is $27.51 and its 200 day simple moving average is $29.57. Pfizer Inc. has a 52-week low of $25.61 and a 52-week high of $42.22. The stock has a market cap of $155.32 billion, a price-to-earnings ratio of 76.19, a PEG ratio of 1.23 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same period last year, the business posted $1.14 EPS. The company's revenue was down 41.3% on a year-over-year basis. Research analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.